HbA1c as a diagnostic tool for diabetes and pre-diabetes: The Bangladesh experience

Diabetic Medicine

Volumn 30, Issue 3, 2013, Pages

  Bhowmik, B ^a   Diep, L M ^a,b   Munir, S B ^c   Rahman, M ^c   Wright, E ^d   Mahmood, S ^e   Afsana, F ^f   Ahmed, T ^f   Khan, A K A ^f   Hussain, A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Diabetic Association of Bangladesh   (Bangladesh)

^d CANBERRA HOSPITAL   (Australia)

^e UNIVERSITY OF DHAKA   (Bangladesh)

^f Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTICLE; BANGLADESH; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GOLD STANDARD; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RURAL POPULATION; SENSITIVITY AND SPECIFICITY;

ADULT; BANGLADESH; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PREDIABETIC STATE; REFERENCE VALUES; ROC CURVE;

EID: 84874128946     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12088     Document Type: Article

References (38)

1. IDF. Diabetes Atlas, 5th edn. Brussels, Belgium: International Diabetes Federation, 2011.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
3. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000; 17: 433-440.
4. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost-effectiveness analysis. Br Med J 2008; 336: 1180-1185.
5. Courten M de, Zimmet P. Screening for non-insulin-dependent diabetes mellitus: where to draw the line? Diabet Med 1997; 14: 95-98.
6. Barr RG, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med 2002; 137: 263-272.
7. The DECODE-Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies.. Diabetologia 1999; 42: 647-654.
8. Little RR. Glycated hemoglobin standardization-national glycohemoglobin standardization program (NGSP) perspective. Clin Chem Lab Med 2003; 41: 1191-1198.
9. IFCC. Website. Available at http://www.ifcc.org/ejifcc/vol13no2/1301200103.htm Last accessed June 2010.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69.
11. 1c as a screening tool for detection of Type 2 diabetes: a systemic review. Diabet Med 2007; 24: 333-343.
12. 1c to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indian: The Strong Heart Study. Diabetes Care 2002; 25: 1365-1370.
13. 1c. Diabetes Res Clin Pract 2000; 50: 225-230.
14. McCane DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH et al. Comparison of tests for glycated haemoglobin and fasting and 2-h plasma glucose concentrations as diagnostic methods for diabetes. Br Med J 1994; 308: 1323-1328.
15. 1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-791.
16. WHO International Society of Hypertension, Guidelines Subcommittee. Guidelines for the management of gypertension. J Hypertens 1999; 17: 151-183.
17. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007; 96: 644-647.
18. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
19. Stata Corporation. Stata/IC 11 for Windows. College Station: StataCorp LP, 2009.
20. SPSS. PASW Statistics 18, release rersion 18.0.0. Chicago: SPSS, 2009. Available at http://www.spss.com Last accessed September 2009.
21. International Expert Committee. Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
22. American Association of Clinical Endocrinologists. American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract 2010; 16: 155-156.
23. 1c for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing. Diabet Med 2009; 26: 1262-1268.
24. Snehalatha C, Ramachandran A, Satyavani K, Vijay V. Limitations of glycosylated haemoglobin as an index of glucose intolerance. Diabetes Res Clin Pract 2000; 47: 129-133.
25. Lipska KJ, De Rekeneire N, Ness Van PH, Johnson KC, Kanaya A, Koster A et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. J Clin Endocrinol. Metab 2010; 95: 5289-5295.
26. 1c values for defining diabetes and impaired fasting glucose in Asian Indians. Primary Care Diabetes 2011; 5: 95-102.
27. Colagiuri S, Hussain Z, Zimmet P, Cameron A, Shaw J. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004; 27: 367-371.
28. Saydah SH, Byrd-Holt D, Harris MI. Projected impact of implementing the results of the diabetes prevention program in the US population. Diabetes Care 2002; 25: 1940-194.
29. Mannucci E, Ognibene A, Sposato I, Brogi M, Gallori G, Bardini G et al. Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2003; 40: 181-186.
30. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
31. 1c. Diabetes Res Clin Pract 2000; 50: 225-230.
32. 1c and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med 2009; 26: 115-121.
33. WHO/IDF. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF consultation. Available at http://www.who.int/diabetes/publications/Definition%20and%20diagnosisofdiabetes_new.pdf Last accessed 14 January 2006.
34. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 2009; 32: 193-203.
35. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
36. Moses RG, Patterson MJ, Regan JM, Chaunchaiyakul R, Taylor NA, Jenkins AB. A non-linear effect of ambient temperature on apparent glucose tolerance. Diabetes Res Clin Pract 1997; 36: 35-40.
37. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes 1978; 27: 715-725.
38. Talukder MSH, Khan AK, Ali SMK, Vaaler S, Hussain A. Consistency of fasting blood glucose and oral glucose tolerance test: a hospital-based study in Bangladesh. J Diabetol 2010; 1: 4.